Log in to save to my catalogue

Suppression of hypothalamic–pituitary–gonadal function by linzagolix in benign prostatic hyperplasia...

Suppression of hypothalamic–pituitary–gonadal function by linzagolix in benign prostatic hyperplasia...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2857841336

Suppression of hypothalamic–pituitary–gonadal function by linzagolix in benign prostatic hyperplasia and polycystic ovary syndrome animal models

About this item

Full title

Suppression of hypothalamic–pituitary–gonadal function by linzagolix in benign prostatic hyperplasia and polycystic ovary syndrome animal models

Publisher

Richmond: Wiley Subscription Services, Inc

Journal title

Clinical and experimental pharmacology & physiology, 2023-11, Vol.50 (11), p.914-923

Language

English

Formats

Publication information

Publisher

Richmond: Wiley Subscription Services, Inc

More information

Scope and Contents

Contents

The hypothalamic–pituitary–gonadal (HPG) axis is an important regulatory mechanism involved primarily in the development and regulation of the reproductive systems. The suppression of the HPG axis by gonadotropin‐releasing hormone (GnRH) analogues is expected to be effective for the treatment of sex hormone‐dependent diseases, such as endometriosis...

Alternative Titles

Full title

Suppression of hypothalamic–pituitary–gonadal function by linzagolix in benign prostatic hyperplasia and polycystic ovary syndrome animal models

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2857841336

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2857841336

Other Identifiers

ISSN

0305-1870

E-ISSN

1440-1681

DOI

10.1111/1440-1681.13817

How to access this item